Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 17/20 | 0.62 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.62 |
| ▸ | ATXN2 | Q99700 | 15/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16963605 | 1.00 | ENPP2 (0.62) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL16963254 | 0.94 | ENPP2 (0.55) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL18687399 | 0.90 | ENPP2 (0.77) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL16963535 | 0.90 | ENPP2 (0.77) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL21322972 | 0.90 | ENPP2 (0.77) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL16962686 | 0.90 | ENPP2 (0.77) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL16963821 | 0.90 | ENPP2 (0.61) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL21323076 | 0.87 | ENPP2 (0.66) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL16963831 | 0.87 | ENPP2 (0.66) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL16962522 | 0.86 | ENPP2 (0.59) | ENPP2DGAT2ATXN2HTR2AABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10669268-B2 | Bicyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | CCNY, BICRA, UQCRB | ENPP2 1716/4885DGAT2 3583/4885ATXN2 669/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | ENPP2 1716/4885DGAT2 3583/4885ATXN2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.